Subscribe To
Bio-key international announces closing of $3.75 million public offering
HOLMDEL, N.J., Oct. 31, 2023 (GLOBE NEWSWIRE) — BIO-key® International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer Ident...
October 31, 2023, 8:15 pm
Arcutis announces pricing of $100 million public offering
WESTLAKE VILLAGE, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) (“Arcutis”), an early commercial-stage b...
October 20, 2023, 3:45 am
Versus systems inc. announces pricing of $3.0 million public offering
LOS ANGELES, Oct. 13, 2023 (GLOBE NEWSWIRE) — Versus Systems Inc. (“Versus” or the “Company”) (NASDAQ: VS), today announced the pricing of i...
October 13, 2023, 3:55 pm
Cerevel therapeutics announces pricing of $450 million public offering of common stock
CAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) — Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE), a company dedicated to unraveling the mysteri...
October 12, 2023, 2:45 am
Transcode therapeutics announces closing of $8.5 million public offering
BOSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more...
September 28, 2023, 8:02 pm
Transcode therapeutics announces pricing of $8 million public offering
BOSTON, Sept. 25, 2023 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to mor...
September 26, 2023, 12:01 am
Cymabay announces closing of upsized $258.7 million public offering of common stock and pre-funded warrants, including full exercise of underwriters’ option to purchase additional shares
NEWARK, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on d...
September 14, 2023, 8:57 pm
Grom social enterprises, inc. announces closing of $3.0 million public offering
BOCA RATON, Fla., Sept. 12, 2023 (GLOBE NEWSWIRE) — Grom Social Enterprises, Inc. (NASDAQ: GROM; GROMW) (the “Company”), today closed its previo...
September 12, 2023, 8:31 pm
Cymabay announces pricing of upsized $225 million public offering of common stock and pre-funded warrants
NEWARK, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on d...
September 12, 2023, 2:15 am
Blue star foods announces pricing of $5 million public offering
Miami, FL, Sept. 07, 2023 (GLOBE NEWSWIRE) — Blue Star Foods Corp., (“Blue Star,” the “Company,” “we,” “our” or “us”) (NASDAQ: B...
September 7, 2023, 1:20 pm
Societal cdmo announces closing of $8.3 million public offering of common stock
SAN DIEGO and GAINESVILLE, Ga., Aug. 29, 2023 (GLOBE NEWSWIRE) — Societal CDMO, Inc. (“Societal”; NASDAQ: SCTL), a contract development and manu...
August 29, 2023, 11:00 am
Yield10 bioscience announces closing of $3.7 million public offering
WOBURN, Mass., Aug. 15, 2023 (GLOBE NEWSWIRE) — Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscie...
August 15, 2023, 5:00 pm
Adamis pharmaceuticals announces closing of $8.0 million public offering
SAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today a...
August 4, 2023, 5:43 pm
Bio-path holdings, inc. announces pricing of $2.1 million public offering
HOUSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (Nasdaq:BPTH) (“Bio-Path” or the “Company”), a biotechnology company leve...
August 3, 2023, 12:22 pm
Tonix pharmaceuticals announces pricing of $7 million public offering
CHATHAM, N.J., July 27, 2023 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a biopharmace...
July 28, 2023, 1:31 am
Acumen announces pricing of upsized $130 million public offering
CHARLOTTESVILLE, Va. and CARMEL, Ind., July 18, 2023 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc. (“Acumen”) (NASDAQ: ABOS), a clinical-stage...
July 19, 2023, 2:31 am
Immunogen: comprehensive mirasol data reinforces elahere's potential
ImmunoGen's Q1 2023 revenue increased to $49.9 million, primarily due to sales of Elahere and an upfront fee from Vertex Pharmaceuticals. The company ...
July 6, 2023, 9:31 pm
C3is inc. announces pricing of $5 million public offering
ATHENS, Greece, June 30, 2023 (GLOBE NEWSWIRE) — C3is Inc. (Nasdaq: CISS) (the “Company”), a ship-owning company providing drybulk seaborne tran...
June 30, 2023, 1:15 pm
Cormedix inc. announces pricing of $40 million public offering of common stock and pre-funded warrants
BERKELEY HEIGHTS, N.J., June 28, 2023 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commerc...
June 29, 2023, 2:57 am
Toughbuilt industries announces closing of $4.5 million public offering
IRVINE, Calif., June 23, 2023 (GLOBE NEWSWIRE) — ToughBuilt Industries, Inc. (“ToughBuilt” or the “Company”) (NASDAQ: TBLT; TBLTW), today an...
June 23, 2023, 8:05 pm